Bracco, a global leader in diagnostic imaging, today announced that the U.S. Food and Drug Administration (FDA) has approved ...
Guerbet's innovation, Elucirem™ is the first gadolinium-based contrast agent approved at half dose of gadolinium, and with ...
PRINCETON, N.J., Nov. 11, 2024 /PRNewswire/ -- Bracco Diagnostics Inc., the U.S. subsidiary of Bracco Imaging S.p.A., a leading global company in the diagnostic imaging business, is proud to announce ...
Clariscan, approved in more than 55 countries globally with over four million patient doses shipped, is now FDA-approved in the U.S. Expands the GE Healthcare portfolio of contrast media products “The ...
MARLBOROUGH, Mass.--(BUSINESS WIRE)--GE Healthcare’s innovative shatterproof polymer +PLUSPAK Pharmacy Bulk Package has been approved by the US FDA for use with its macrocyclic gadolinium-based MRI ...
We are looking for volunteers to undergo magnetic resonance imaging (MRI) scans of the brain, with gadolinium-based contrast agent injection. Participants will be paid $80. The total scan duration is ...
In the U.S., Elucirem is indicated in adults and now in pediatric patients including term neonates, for use with magnetic resonance imaging (MRI) to detect and visualize lesions with abnormal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results